Tenapanor, the NHE3 sodium transporter inhibitor that yielded positive phase IIb data last fall in constipation-predominant irritable bowel syndrome (IBS-C) for Ardelyx Inc. and partner Astrazeneca plc, hit its efficacy endpoint in a second indication, but disappointed investors with "distinctly" higher-than-expected instances of diarrhea.